Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Continues Safety Policy Limiting Teenage Use Of Tamiflu

This article was originally published in PharmAsia News

Executive Summary

The Drug Safety Committee at the Pharmaceutical and Food Sanitization Council of Japan's Ministry of Health, Labor and Welfare June 16 decided to continue its current safety measure of limiting Tamiflu (oseltamivir) use in minors over 10 years of age. The committee's decision was based on two working group's scientific and clinical findings, which noted that although there was no statistical significance between Tamiflu users and non-users in the age group, the users had 1.54 times higher risk of developing abnormal behavior. The groups also stated that the research couldn't establish a casual relationship between taking Tamiflu and abnormal behavior. The safety policy was initiated in March 2007 when the Ministry received reports of teenagers showing abnormal behaviors after taking Tamiflu. (Click here for more - Japanese Language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071924

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel